SITENSA

*Nausea and vomiting induced by cytotoxic chemotherapy:* BY TRANSDERMAL PATCHES: Adult: For planned duration of 3-5 days where oral antiemetics cannot be used, apply 3.1 mg/24 hours, apply patch to clean, dry, non-irritated, non-hairy skin on upper arm (or abdomen if upper arm cannot be used) 24-48 hours before treatment, patch may be worn for up to 7 days; remove at least 24 hours after completing chemotherapy *Prevention of postoperative nausea and vomiting:* BY IV INJ: Adult: 1 mg, to be administered before induction of anaesthesia, dose to be diluted to 5ml and given over 30 seconds *Treatment of postoperative nausea and vomiting:* BY IV INJ: Adult: 1 mg, dose to be diluted to 5ml and given over30 seconds; max. 3 mg per day *Management of nausea and vomiting induced by cytotoxic chemotherapy or radiotherapy:* ORAL: Adult: 1-2 mg, to be taken within 1 hour before start of treatment, then 2 mg daily in 1-2 divided doses for up to 1 week following treatment, when IV route also used, max. combined total dose 9mg in24 hours BY IV INJ, OR BY IV INF: Adult: 10-40 mcg/kg (max. per dose 3 mg), tobe given 5 minutes before start of treatment, dose maybe repeated if necessary, further maintenance doses must not be given less than 10 minutes apart; max. 9 mg per day. Children: Not recommended.

For IV injection, each 1 mg Granisetron diluted to 5ml and given over not less than 30 seconds, for IV infusion, to be given over 5 minutes.

Hepatic impairment, Sub-acute intestinal obstruction, susceptibility to QT-interval prolongation (including electrolyte disturbances).

Constipation, diarrhoea, headache, insomnia, transient rise in liver enzymes, extrapyramidal reactions, QT-interval prolongation, rash, with transdermal use application-site reactions.